Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter March 15, 2019

Evaluation of the possible interference of abiraterone therapy on testosterone immunoassay

Ruggero Dittadi EMAIL logo , Vania Polesello , Andrea Zivi and Paolo Carraro
  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: None declared.

  3. Employment or leadership: None declared.

  4. Honorarium: None declared.

  5. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.


1. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014;65:467–79.10.1016/j.eururo.2013.11.002Search in Google Scholar

2. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008;68:4447–54.10.1158/0008-5472.CAN-08-0249Search in Google Scholar

3. Attard G, Reid AH, A’Hern R, Parker C, Ommen NB, Folkerd E, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009;27:3742–8.10.1200/JCO.2008.20.0642Search in Google Scholar

4. O’Donnell A, Judson I, Dowsett M, Raynaud F, Dearnaley D, Mason M, et al. Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 2004;90:2317–25.10.1038/sj.bjc.6601879Search in Google Scholar

5. Thakur A, Roy A, Ghosh A, Chhabra M, Banerjee S. Abiraterone acetate in the treatment of prostate cancer. Biomed Pharmacother 2018;101:211–8.10.1016/j.biopha.2018.02.067Search in Google Scholar

6. Fairfax BP, Morgan RD, Protheroe A, Shine B, James T. Abiraterone acetate: a potential source of interference in testosterone assays. Clin Chem Lab Med 2018;56:e138–40.10.1515/cclm-2017-0631Search in Google Scholar

7. Dittadi R, Matteucci M, Meneghetti E, Ndreu R. Reassessment of the access testosterone chemiluminescence assay and comparison with LC-MS method. J Clin Lab Anal 2018;32:e22286.10.1002/jcla.22286Search in Google Scholar

8. Meani D, Solarić M, Visapää H, Rosén RM, Janknegt R, Soče M. Practical differences between luteinizing hormone-releasing hormone agonists in prostate cancer: perspectives across the spectrum of care. Ther Adv Urol 2017;10:51–63.10.1177/1756287217738985Search in Google Scholar

9. Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008;26:4563–71.10.1200/JCO.2007.15.9749Search in Google Scholar

10. Ryan CJ, Smith MR, Fong L, Rosenberg JE, Kantoff P, RaynaudF, et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010;28:1481–8.10.1200/JCO.2009.24.1281Search in Google Scholar

Received: 2018-12-04
Accepted: 2019-02-16
Published Online: 2019-03-15
Published in Print: 2019-09-25

©2019 Walter de Gruyter GmbH, Berlin/Boston

Downloaded on 26.1.2023 from
Scroll Up Arrow